Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DarioHealth Corp DRIO

DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.


NDAQ:DRIO - Post by User

Post by drbob512on Aug 08, 2020 11:08pm
126 Views
Post# 31383814

Every DRIO pullback

Every DRIO pullbackhas been met with dip buyers in a major way, leading to blue sky breakout. While 18.84 is now the ATH, the stock has come up a lot in past few wks. ER is Aug 12 and i dont expect great news on revenue growth but the $28.6M raised has transformed this company to be able to do something now. Comments from the ER are maybe more important than the financial stats for the qtr. Only 3.7M sh before secondary which raises it to only 6.7M shares. This play is risky & speculative but there must be a reason for those institutions to invest in this company; i.e. they see the potential. Hope co. can execute...Jmho dyodd
<< Previous
Bullboard Posts
Next >>